Gary E. Zurenko

4.5k total citations · 1 hit paper
65 papers, 3.4k citations indexed

About

Gary E. Zurenko is a scholar working on Molecular Biology, Organic Chemistry and Pharmacology. According to data from OpenAlex, Gary E. Zurenko has authored 65 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 25 papers in Organic Chemistry and 21 papers in Pharmacology. Recurrent topics in Gary E. Zurenko's work include Antibiotic Resistance in Bacteria (18 papers), Antimicrobial Resistance in Staphylococcus (16 papers) and Synthesis and biological activity (14 papers). Gary E. Zurenko is often cited by papers focused on Antibiotic Resistance in Bacteria (18 papers), Antimicrobial Resistance in Staphylococcus (16 papers) and Synthesis and biological activity (14 papers). Gary E. Zurenko collaborates with scholars based in United States. Gary E. Zurenko's co-authors include Michael R. Barbachyn, Douglas K. Hutchinson, Ronda D. Schaadt, Charles W. Ford, Betty H. Yagi, Steven J. Brickner, Kevin C. Grega, Stuart A. Garmon, Dana S. Toops and Susan K. Hendges and has published in prestigious journals such as Journal of the American Chemical Society, Clinical Infectious Diseases and Journal of Clinical Microbiology.

In The Last Decade

Gary E. Zurenko

65 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms Haemophilus influenzae and Moraxella catarrhalis

2000 662 citations Michaël Génin, Michael R. Barbachyn et al. Journal of Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary E. Zurenko United States	26	1.6k	1.2k	1.2k	602	520	65	3.4k
Michael R. Barbachyn United States	23	2.1k 1.4×	1.1k 0.9×	1.4k 1.2×	499 0.8×	409 0.8×	38	3.7k
Steven J. Brickner United States	19	966 0.6×	1.1k 0.9×	822 0.7×	366 0.6×	318 0.6×	32	2.3k
Douglas K. Hutchinson United States	17	1.4k 0.9×	886 0.7×	924 0.8×	324 0.5×	276 0.5×	21	2.5k
N H Georgopapadakou United States	30	697 0.4×	1.1k 0.9×	1.5k 1.3×	1.1k 1.9×	979 1.9×	86	3.8k
D P Bonner United States	30	497 0.3×	824 0.7×	764 0.6×	1.1k 1.8×	929 1.8×	72	2.9k
Robert J. Kerns United States	29	1.2k 0.8×	565 0.5×	2.6k 2.2×	997 1.7×	1.3k 2.5×	75	4.1k
Lynn L. Silver United States	36	894 0.6×	654 0.5×	2.5k 2.1×	1.0k 1.7×	1.7k 3.4×	73	5.4k
Thomas D. Gootz United States	36	487 0.3×	490 0.4×	1.3k 1.1×	1.2k 1.9×	1.5k 2.9×	60	3.4k
John M. Domagala United States	27	1.0k 0.7×	657 0.5×	1.4k 1.2×	1.1k 1.9×	941 1.8×	62	3.2k
Frederick M. Kahan United States	16	791 0.5×	380 0.3×	1.1k 0.9×	1.5k 2.6×	1.4k 2.7×	17	3.6k

Countries citing papers authored by Gary E. Zurenko

Since Specialization

Citations

This map shows the geographic impact of Gary E. Zurenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary E. Zurenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary E. Zurenko more than expected).

Fields of papers citing papers by Gary E. Zurenko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary E. Zurenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary E. Zurenko. The network helps show where Gary E. Zurenko may publish in the future.

Co-authorship network of co-authors of Gary E. Zurenko

This figure shows the co-authorship network connecting the top 25 collaborators of Gary E. Zurenko. A scholar is included among the top collaborators of Gary E. Zurenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary E. Zurenko. Gary E. Zurenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Locke, Jeffrey B., Gary E. Zurenko, Karen Joy Shaw, & Kenneth F. Bartizal. (2013). Tedizolid for the Management of Human Infections: In Vitro Characteristics. Clinical Infectious Diseases. 58(suppl_1). S35–S42. 86 indexed citations

Morris, Timothy W., et al.. (2009). Clinical Efficacy of Besifloxacin Ophthalmic Suspension; Integrated Microbiological Results of 3 Trials for Topical Treatment of Bacterial Conjunctivitis. Investigative Ophthalmology & Visual Science. 50(13). 5945–5945. 1 indexed citations

Zurenko, Gary E.. (2008). Specific Spectrum Activity of AFN-1252 Against Aerobic and Anaerobic Bacterial Pathogens. 46th Annual Meeting. 2 indexed citations

Thorarensen, Atli, Donna L. Romero, Keith R. Marotti, et al.. (2007). Preparation of novel anthranilic acids as antibacterial agents. Extensive evaluation of alternative amide bioisosteres connecting the A- and the B-rings. Bioorganic & Medicinal Chemistry Letters. 17(10). 2823–2827. 14 indexed citations

Stiff, Cory M., Min Zhong, Ronald W. Sarver, et al.. (2007). Correlation of carboxylic acid pKa to protein binding and antibacterial activity of a novel class of bacterial translation inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(19). 5479–5482. 5 indexed citations

Stiff, Cory M., David R. Graber, Atli Thorarensen, et al.. (2007). Bacterial translation inhibitors, 1-acylindazol-3-ols as anthranilic acid mimics. Bioorganic & Medicinal Chemistry Letters. 18(23). 6293–6297. 9 indexed citations

Ciske, Fred L., Michael R. Barbachyn, Michaël Génin, et al.. (2003). The effect of remote chirality on the antibacterial activity of indolinyl, tetrahydroquinolyl and dihydrobenzoxazinyl oxazolidinones. Bioorganic & Medicinal Chemistry Letters. 13(23). 4235–4239. 22 indexed citations

GORDEEV, M. F., C J Hackbarth, Michael R. Barbachyn, et al.. (2003). Novel oxazolidinone–quinolone hybrid antimicrobials. Bioorganic & Medicinal Chemistry Letters. 13(23). 4213–4216. 54 indexed citations

Thorarensen, Atli, et al.. (2001). Enols as Potent Antibacterial Agents. Bioorganic & Medicinal Chemistry Letters. 11(22). 2931–2934. 3 indexed citations

10.

Zurenko, Gary E., et al.. (1997). Oxazolidinone antibacterial agents: development of the clinical candidates eperezolid and linezolid. Expert Opinion on Investigational Drugs. 6(2). 151–158. 33 indexed citations

11.

Schaadt, Ronda D., et al.. (1997). Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid. Diagnostic Microbiology and Infectious Disease. 28(4). 201–204. 24 indexed citations

12.

Ford, Charles W., Judith C. Hamel, Douglas Stapert, et al.. (1997). Oxazolidinones: New antibacterial agents. Trends in Microbiology. 5(5). 196–200. 56 indexed citations

13.

Yagi, Betty H. & Gary E. Zurenko. (1997). In vitroActivity of Linezolid and Eperezolid, Two Novel Oxazolidinone Antimicrobial Agents, Against Anaerobic Bacteria. Anaerobe. 3(5). 301–306. 13 indexed citations

14.

Žemlička, Jiří, et al.. (1993). Hybrids of antibiotics inhibiting protein synthesis. Synthesis and biological activity. Journal of Medicinal Chemistry. 36(9). 1239–1244. 12 indexed citations

15.

Jones, Ronald N. & Gary E. Zurenko. (1993). Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result. Diagnostic Microbiology and Infectious Disease. 17(4). 313–316. 14 indexed citations

16.

Brickner, Steven J., et al.. (1992). N-Acyl 3-alkylidenyl- and 3-alkyl azetidin-2-ones: A new class of monocyclic .BETA.-lactam antibacterial agents. 1. Structure-activity relationships of 3-isopropylidene and 3-isopropyl analogs.. The Journal of Antibiotics. 45(2). 213–226. 10 indexed citations

17.

Yagi, Betty H., Ronda D. Schaadt, & Gary E. Zurenko. (1992). The bactericidal activity and postantibiotic effect of trospectomycin. Diagnostic Microbiology and Infectious Disease. 15(5). 417–423. 6 indexed citations

18.

Brunden, Marshall N., Betty H. Yagi, Michael S. Lajiness, & Gary E. Zurenko. (1991). Estimating the postantibiotic effect: A two-phase mathematical model. Journal of Pharmacokinetics and Biopharmaceutics. 19(4). 457–468. 2 indexed citations

19.

Truesdell, S. E., Gary E. Zurenko, & A. L. LABORDE. (1989). Interaction of cephalosporins with penicillin-binding proteins of methicillin-resistant Stapbylococcus aureus. Journal of Antimicrobial Chemotherapy. 23(suppl D). 13–19. 11 indexed citations

20.

Zurenko, Gary E., et al.. (1988). Trospectomycin, a novel spectinomycin analogue: antibacterial activity and preliminary human pharmacokinetics.. PubMed. 14(6). 403–9. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact